The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Sustained-release Medicine Market Research Report 2025
Synopsis
Sustained-release Medicine refer to preparations that can be continuously released for a long time after administration to achieve long-acting effects, and the drug release is mainly a first-order rate process. Controlled release preparations (controlled release preparations) refer to the preparations that can automatically release the drug at a predetermined speed within a predetermined time, so that the blood drug concentration can be kept constant within the effective concentration range for a long time.
Since there is no difference between sustained-release preparations and controlled-release preparations in the some countries, so, in this report, Extended release (ER), Sustained release (SR), Controlled release (CR) and Delayed release (D
The global Sustained-release Medicine market was valued at US$ 34850 million in 2023 and is anticipated to reach US$ 55040 million by 2030, witnessing a CAGR of 6.9% during the forecast period 2024-2030.
The main global manufacturers of sustained-release drugs are Sanofi, Novartis, Bayer, Johnson & Johnson, Takeda, AstraZeneca, AbbVie, etc. The top seven manufacturers occupy a total market share of nearly 35%, of which the largest manufacturer is Sanofi, with a market share of 10.85%. Global sustained-release drug production regions are mainly located in Europe, the United States, China, etc., of which the top two regions occupy more than 65% of the market share. In terms of their product categories, original ground medicine have a higher market share of 63.96%, while generics have a lower share.
This report aims to provide a comprehensive presentation of the global market for Sustained-release Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sustained-release Medicine.
Report Scope
The Sustained-release Medicine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sustained-release Medicine market comprehensively. Regional market sizes, concerning products by Type, by Distribution Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sustained-release Medicine companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Distribution Channel, and by regions.
Market Segmentation
By Company
Sanofi
Novartis
Bayer
Johnson & Johnson
Takeda
AstraZeneca
AbbVie
Pfizer
Collegium Pharmaceutical, Inc
Endo Pharmaceuticals
Shanghai Shyndec Pharmaceutical
Zhuhai Rundu Pharmaceutical
China Res Double-Crane
Segment by Type
Original Ground Medicine
Generic Medicine
Segment by Distribution Channel
Hospital
Drugstore
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Distribution Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sustained-release Medicine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Sustained-release Medicine refer to preparations that can be continuously released for a long time after administration to achieve long-acting effects, and the drug release is mainly a first-order rate process. Controlled release preparations (controlled release preparations) refer to the preparations that can automatically release the drug at a predetermined speed within a predetermined time, so that the blood drug concentration can be kept constant within the effective concentration range for a long time.
Since there is no difference between sustained-release preparations and controlled-release preparations in the some countries, so, in this report, Extended release (ER), Sustained release (SR), Controlled release (CR) and Delayed release (D
The global Sustained-release Medicine market was valued at US$ 34850 million in 2023 and is anticipated to reach US$ 55040 million by 2030, witnessing a CAGR of 6.9% during the forecast period 2024-2030.
The main global manufacturers of sustained-release drugs are Sanofi, Novartis, Bayer, Johnson & Johnson, Takeda, AstraZeneca, AbbVie, etc. The top seven manufacturers occupy a total market share of nearly 35%, of which the largest manufacturer is Sanofi, with a market share of 10.85%. Global sustained-release drug production regions are mainly located in Europe, the United States, China, etc., of which the top two regions occupy more than 65% of the market share. In terms of their product categories, original ground medicine have a higher market share of 63.96%, while generics have a lower share.
This report aims to provide a comprehensive presentation of the global market for Sustained-release Medicine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Sustained-release Medicine.
Report Scope
The Sustained-release Medicine market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Sustained-release Medicine market comprehensively. Regional market sizes, concerning products by Type, by Distribution Channel, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Sustained-release Medicine companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Distribution Channel, and by regions.
Market Segmentation
By Company
Sanofi
Novartis
Bayer
Johnson & Johnson
Takeda
AstraZeneca
AbbVie
Pfizer
Collegium Pharmaceutical, Inc
Endo Pharmaceuticals
Shanghai Shyndec Pharmaceutical
Zhuhai Rundu Pharmaceutical
China Res Double-Crane
Segment by Type
Original Ground Medicine
Generic Medicine
Segment by Distribution Channel
Hospital
Drugstore
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Distribution Channel, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Sustained-release Medicine companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Distribution Channel, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Sustained-release Medicine Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Original Ground Medicine
1.2.3 Generic Medicine
1.3 Market by Distribution Channel
1.3.1 Global Sustained-release Medicine Market Growth by Distribution Channel: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Drugstore
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Sustained-release Medicine Market Perspective (2019-2030)
2.2 Sustained-release Medicine Growth Trends by Region
2.2.1 Global Sustained-release Medicine Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Sustained-release Medicine Historic Market Size by Region (2019-2024)
2.2.3 Sustained-release Medicine Forecasted Market Size by Region (2025-2030)
2.3 Sustained-release Medicine Market Dynamics
2.3.1 Sustained-release Medicine Industry Trends
2.3.2 Sustained-release Medicine Market Drivers
2.3.3 Sustained-release Medicine Market Challenges
2.3.4 Sustained-release Medicine Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Sustained-release Medicine Players by Revenue
3.1.1 Global Top Sustained-release Medicine Players by Revenue (2019-2024)
3.1.2 Global Sustained-release Medicine Revenue Market Share by Players (2019-2024)
3.2 Global Sustained-release Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Sustained-release Medicine Revenue
3.4 Global Sustained-release Medicine Market Concentration Ratio
3.4.1 Global Sustained-release Medicine Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Sustained-release Medicine Revenue in 2023
3.5 Sustained-release Medicine Key Players Head office and Area Served
3.6 Key Players Sustained-release Medicine Product Solution and Service
3.7 Date of Enter into Sustained-release Medicine Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Sustained-release Medicine Breakdown Data by Type
4.1 Global Sustained-release Medicine Historic Market Size by Type (2019-2024)
4.2 Global Sustained-release Medicine Forecasted Market Size by Type (2025-2030)
5 Sustained-release Medicine Breakdown Data by Distribution Channel
5.1 Global Sustained-release Medicine Historic Market Size by Distribution Channel (2019-2024)
5.2 Global Sustained-release Medicine Forecasted Market Size by Distribution Channel (2025-2030)
6 North America
6.1 North America Sustained-release Medicine Market Size (2019-2030)
6.2 North America Sustained-release Medicine Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Sustained-release Medicine Market Size by Country (2019-2024)
6.4 North America Sustained-release Medicine Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Sustained-release Medicine Market Size (2019-2030)
7.2 Europe Sustained-release Medicine Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Sustained-release Medicine Market Size by Country (2019-2024)
7.4 Europe Sustained-release Medicine Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Sustained-release Medicine Market Size (2019-2030)
8.2 Asia-Pacific Sustained-release Medicine Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Sustained-release Medicine Market Size by Region (2019-2024)
8.4 Asia-Pacific Sustained-release Medicine Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Sustained-release Medicine Market Size (2019-2030)
9.2 Latin America Sustained-release Medicine Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Sustained-release Medicine Market Size by Country (2019-2024)
9.4 Latin America Sustained-release Medicine Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Sustained-release Medicine Market Size (2019-2030)
10.2 Middle East & Africa Sustained-release Medicine Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Sustained-release Medicine Market Size by Country (2019-2024)
10.4 Middle East & Africa Sustained-release Medicine Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Sanofi
11.1.1 Sanofi Company Detail
11.1.2 Sanofi Business Overview
11.1.3 Sanofi Sustained-release Medicine Introduction
11.1.4 Sanofi Revenue in Sustained-release Medicine Business (2019-2024)
11.1.5 Sanofi Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Sustained-release Medicine Introduction
11.2.4 Novartis Revenue in Sustained-release Medicine Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Bayer
11.3.1 Bayer Company Detail
11.3.2 Bayer Business Overview
11.3.3 Bayer Sustained-release Medicine Introduction
11.3.4 Bayer Revenue in Sustained-release Medicine Business (2019-2024)
11.3.5 Bayer Recent Development
11.4 Johnson & Johnson
11.4.1 Johnson & Johnson Company Detail
11.4.2 Johnson & Johnson Business Overview
11.4.3 Johnson & Johnson Sustained-release Medicine Introduction
11.4.4 Johnson & Johnson Revenue in Sustained-release Medicine Business (2019-2024)
11.4.5 Johnson & Johnson Recent Development
11.5 Takeda
11.5.1 Takeda Company Detail
11.5.2 Takeda Business Overview
11.5.3 Takeda Sustained-release Medicine Introduction
11.5.4 Takeda Revenue in Sustained-release Medicine Business (2019-2024)
11.5.5 Takeda Recent Development
11.6 AstraZeneca
11.6.1 AstraZeneca Company Detail
11.6.2 AstraZeneca Business Overview
11.6.3 AstraZeneca Sustained-release Medicine Introduction
11.6.4 AstraZeneca Revenue in Sustained-release Medicine Business (2019-2024)
11.6.5 AstraZeneca Recent Development
11.7 AbbVie
11.7.1 AbbVie Company Detail
11.7.2 AbbVie Business Overview
11.7.3 AbbVie Sustained-release Medicine Introduction
11.7.4 AbbVie Revenue in Sustained-release Medicine Business (2019-2024)
11.7.5 AbbVie Recent Development
11.8 Pfizer
11.8.1 Pfizer Company Detail
11.8.2 Pfizer Business Overview
11.8.3 Pfizer Sustained-release Medicine Introduction
11.8.4 Pfizer Revenue in Sustained-release Medicine Business (2019-2024)
11.8.5 Pfizer Recent Development
11.9 Collegium Pharmaceutical, Inc
11.9.1 Collegium Pharmaceutical, Inc Company Detail
11.9.2 Collegium Pharmaceutical, Inc Business Overview
11.9.3 Collegium Pharmaceutical, Inc Sustained-release Medicine Introduction
11.9.4 Collegium Pharmaceutical, Inc Revenue in Sustained-release Medicine Business (2019-2024)
11.9.5 Collegium Pharmaceutical, Inc Recent Development
11.10 Endo Pharmaceuticals
11.10.1 Endo Pharmaceuticals Company Detail
11.10.2 Endo Pharmaceuticals Business Overview
11.10.3 Endo Pharmaceuticals Sustained-release Medicine Introduction
11.10.4 Endo Pharmaceuticals Revenue in Sustained-release Medicine Business (2019-2024)
11.10.5 Endo Pharmaceuticals Recent Development
11.11 Shanghai Shyndec Pharmaceutical
11.11.1 Shanghai Shyndec Pharmaceutical Company Detail
11.11.2 Shanghai Shyndec Pharmaceutical Business Overview
11.11.3 Shanghai Shyndec Pharmaceutical Sustained-release Medicine Introduction
11.11.4 Shanghai Shyndec Pharmaceutical Revenue in Sustained-release Medicine Business (2019-2024)
11.11.5 Shanghai Shyndec Pharmaceutical Recent Development
11.12 Zhuhai Rundu Pharmaceutical
11.12.1 Zhuhai Rundu Pharmaceutical Company Detail
11.12.2 Zhuhai Rundu Pharmaceutical Business Overview
11.12.3 Zhuhai Rundu Pharmaceutical Sustained-release Medicine Introduction
11.12.4 Zhuhai Rundu Pharmaceutical Revenue in Sustained-release Medicine Business (2019-2024)
11.12.5 Zhuhai Rundu Pharmaceutical Recent Development
11.13 China Res Double-Crane
11.13.1 China Res Double-Crane Company Detail
11.13.2 China Res Double-Crane Business Overview
11.13.3 China Res Double-Crane Sustained-release Medicine Introduction
11.13.4 China Res Double-Crane Revenue in Sustained-release Medicine Business (2019-2024)
11.13.5 China Res Double-Crane Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
